STOCK TITAN
  1. Home
  2. Sec-filings
  3. ARTV
  4. [SCHEDULE 13G/A] Artiva Biotherapeutics, Inc. SEC Filing

[SCHEDULE 13G/A] Artiva Biotherapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ARTV logo
ARTIVA BIOTHERAPEUTICS INC

NASDAQ:ARTV

ARTV Rankings

#6595 Ranked by Market Cap
N/A Ranked by Dividends
#164 Top Loser

ARTV Latest News

Jun 23, 2025
ArrePath Announces Closing of Their Next Financing Round and Appointment of a New Board Chair
May 28, 2025
Artiva Biotherapeutics to Participate in the Jefferies Global Healthcare Conference
May 13, 2025
Artiva Biotherapeutics Announces Longer-term Phase 1/2 Data Demonstrating Prolonged Durability for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting
May 8, 2025
Artiva Biotherapeutics Reports First Quarter 2025 Financial Results, Recent Business Highlights
Apr 28, 2025
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

ARTV Latest SEC Filings

Jun 26, 2025
[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity
Jun 26, 2025
[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity
Jun 26, 2025
[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity
Jun 26, 2025
[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity
Jun 26, 2025
[Form 4] Artiva Biotherapeutics, Inc. Insider Trading Activity

ARTV Stock Data

42.39M
18.29M
22.7%
91.11%
4.63%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO